SHPMF (Shanghai Pharmaceuticals Holding Co) Revenue: $40,826 Mil (TTM As of Mar. 2026)


SHPMF Shanghai Pharmaceuticals Holding Co Ltd SHPMF
73 GF Score
Price $1.46
GF Value $1.82
! 4 Warning Signs
View Full Analysis

What is Shanghai Pharmaceuticals Holding Co Revenue?

Shanghai Pharmaceuticals Holding Co SHPMF -4.58% 73 Revenue is $40,826 Mil as of Mar. 2026. GuruFocus rates SHPMF with a GF Score™ of 73/100 and a GF Value™ of $1.82. The stock has 4 warning signs investors should review.

Shanghai Pharmaceuticals Holding Co's revenue for the three months ended in Mar. 2026 was $10,920 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $40,826 Mil. Shanghai Pharmaceuticals Holding Co's Revenue per Share for the three months ended in Mar. 2026 was $2.93. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $10.97.

During the past 12 months, the average Revenue per Share Growth Rate of Shanghai Pharmaceuticals Holding Co was 4.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 4.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 6.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Shanghai Pharmaceuticals Holding Co's highest 3-Year average Revenue per Share Growth Rate was 141.00% per year. The lowest was -15.40% per year. And the median was 12.70% per year.


Shanghai Pharmaceuticals Holding Co  (OTCPK:SHPMF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Shanghai Pharmaceuticals Holding Co Revenue Related Terms


Shanghai Pharmaceuticals Holding Co Revenue Historical Data

* Premium members only.

The historical data trend for Shanghai Pharmaceuticals Holding Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Pharmaceuticals Holding Co Revenue Chart

Shanghai Pharmaceuticals Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33,885.08 33,274.71 36,454.87 37,805.56 40,262.89

Shanghai Pharmaceuticals Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,761.29 9,864.39 10,315.08 9,726.74 10,920.00

SHPMF vs MCK, CAH, COR: Revenue Comparison

For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Pharmaceuticals Holding Co Revenue vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Revenue falls into.


SHPMF
73GF Score
Shanghai Pharmaceuticals Holding Co Ltd SHPMF
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Pharmaceuticals Holding Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $40,826 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $40,826 Mil mean?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a Revenue of $40,826 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors.
Is Shanghai Pharmaceuticals Holding Co's Revenue too high?
Shanghai Pharmaceuticals Holding Co's current Revenue is $40,826 Mil. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's Revenue compare to MCK and CAH?
Shanghai Pharmaceuticals Holding Co's Revenue of $40,826 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Distribution company?
A good Revenue depends on the Medical Distribution industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. Shanghai Pharmaceuticals Holding Co's current Revenue is $40,826 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a current Revenue of $40,826 Mil. The stock's GF Value™ is $1.82, compared to a current price of $1.46 — trading 19.8% below its estimated fair value. The current Revenue is $40,826 Mil. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMF), the current Revenue is $40,826 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued. The current stock price of $1.46 is trading 19.8% below its estimated GF Value™ of $1.82.

Key valuation signals for SHPMF:

  • Revenue: $40,826 Mil
  • GF Value™: $1.82 vs. price of $1.46 (19.8% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Pharmaceuticals Holding Co Business Description

Address No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
73GF Score

Get the complete analysis for SHPMF

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.46
Price
$1.82
GF Value